ERECTILE - 35 Anuncios
Wednesday 09 July 2025
PT-141 was approved by the FDA in June 2019 for the treatment of acquired, generalized HSDD in premenopausal women. It activates melanocortin receptors. PT-141 is used for the treatment of erectile dysfunction in men and for the treatment of hypoactive ual desire disorder in women...
Chongqing Soarwin Technology Co., Ltd
- 401120 - chongqing
- +18 0 99 30 10 07
- +86 19944061337
Tuesday 08 July 2025
Tadalafil (market name “Cialis” or “Adcirca”) was developed by American pharmaceutical company Lilly. It is a kind of PDE5 inhibitor used for the treatment of erectile dysfunction, benign prostatic hypertrophy and pulmonary arterial hypertension.The effect of Tadalafil is relaxing...
Chongqing Soarwin Technology Co., Ltd
- 401120 - chongqing
- +18 0 99 30 10 07
- +86 19944061337
Friday 04 July 2025
PT-141 was approved by the FDA in June 2019 for the treatment of acquired, generalized HSDD in premenopausal women. It activates melanocortin receptors. PT-141 is used for the treatment of erectile dysfunction in men and for the treatment of hypoactive ual desire disorder in women...
Chongqing Soarwin Technology Co., Ltd
- 401120 - chongqing
- +18 0 99 30 10 07
- +86 19944061337
Thursday 03 July 2025
Tadalafil (market name “Cialis” or “Adcirca”) was developed by American pharmaceutical company Lilly. It is a kind of PDE5 inhibitor used for the treatment of erectile dysfunction, benign prostatic hypertrophy and pulmonary arterial hypertension.The effect of Tadalafil is relaxing...
Chongqing Soarwin Technology Co., Ltd
- 401120 - chongqing
- +18 0 99 30 10 07
- +86 19944061337
Friday 27 June 2025
Tadalafil (market name “Cialis” or “Adcirca”) was developed by American pharmaceutical company Lilly. It is a kind of PDE5 inhibitor used for the treatment of erectile dysfunction, benign prostatic hypertrophy and pulmonary arterial hypertension.The effect of Tadalafil is relaxing...
Chongqing Soarwin Technology Co., Ltd
- 401120 - chongqing
- +18 0 99 30 10 07
- +86 19944061337
Wednesday 25 June 2025
PT-141 was approved by the FDA in June 2019 for the treatment of acquired, generalized HSDD in premenopausal women. It activates melanocortin receptors. PT-141 is used for the treatment of erectile dysfunction in men and for the treatment of hypoactive ual desire disorder in women...
Chongqing Soarwin Technology Co., Ltd
- 401120 - chongqing
- +18 0 99 30 10 07
- +86 19944061337





